Fred E. Cohen - 11 Jun 2025 Form 4 Insider Report for Intellia Therapeutics, Inc. (NTLA)

Reporting relationship: Director
Issuer ticker: NTLA
Reported as of: 11 Jun 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 13 Jun 2025, 16:23:03 UTC
Prior SEC filing: 02 Jun 2025
Next SEC filing: 17 Jun 2025
Source filing: View source filing
Reporting owner signature: Edward Dulac, attorney-in-fact

Key filing fact

Fred E. Cohen filed Form 4 for Intellia Therapeutics, Inc. (NTLA) on 13 Jun 2025.

Key facts

This page summarizes Fred E. Cohen's Form 4 filing for Intellia Therapeutics, Inc. (NTLA).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 13 Jun 2025, 16:23.

Change

Previous filing in this sequence was filed on 02 Jun 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001339358 Primary reporting owner

Cohen Fred E

Relationship: Director
Address: C/O INTELLIA THERAPEUTICS, INC., 40 ERIE STREET; SUITE 130, CAMBRIDGE
Signature: Edward Dulac, attorney-in-fact
Signature date: 13 Jun 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

NTLA transaction

Common Stock

Award

Transaction value: $0
Shares: +8,000
Change %: +16%
Price: $0.000000
Shares after: 57,453
Date: 11 Jun 2025
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

NTLA transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +11,450
Change %
Price: $0.000000
Shares after: 11,450
Date: 11 Jun 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 11,450
Exercise price: $8.37
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit.

Footnote F2

This option was granted on June 11, 2025 with respect to 11,450 shares of Common Stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant.

SEC remarks

Exhibit 24.1 - Power of Attorney